Evidence map›Paper›PMID 41075028›Full record

ReviewMolecular and cellular biochemistry2026

Epigenetic modulation of CTCs as a novel therapeutic target in oncology.

Husni Farah, Munther Kadhim Abosaoda, Hayjaa Mohaisen Mousa, S Renuka Jyothi, Priya Priyadarshini Nayak, J Bethanney Janney, Gurjant Singh, Ashish Singh Chauhan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Husni FarahFaculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
Munther Kadhim AbosaodaCollege of Pharmacy, The Islamic University, Najaf, Iraq. Munthar.Abosaoda@outlook.com.
Hayjaa Mohaisen MousaDepartment of Medicinal Chemistry, Al-Turath University, Al Mansour, Baghdad, 10013, Iraq.
S Renuka JyothiDepartment of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Priya Priyadarshini NayakDepartment of Medical Oncology, IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, 751003, India.
J Bethanney JanneyDepartment of Biomedical, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Gurjant SinghDepartment of Physiotherapy, University Institute of Allied Health Sciences, Chandigarh University, Chandigarh, Punjab, India.
Ashish Singh ChauhanDivision of Research and Innovation, Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor metastasis is the primary cause of high mortality rates among cancer patients. Invasive tumor cells disseminate through the bloodstream as circulating tumor cells (CTCs) and subsequently colonize secondary organs. In addition to genetic mutations that govern biological processes, epigenetic alterations also regulate tumor cell gene expression and chromosome stability. Dysregulation of these patterns is pivotal to carcinogenesis, tumor progression, and metastasis. This narrative review initiates with a comprehensive overview of the biology of CTCs and the processes that contribute to epithelial-mesenchymal transition (EMT), immune surveillance, and colonization. Subsequently, the impact of epigenetic modifications in CTCs on these metastatic processes during CTC migration, survival, and dissemination will be examined. In addition, the paper presents the implications of targeting epigenetics in CTCs for cancer patients and introduces CTCs as new biomarkers for early detection, prognosis, and targeted therapies to improve patient outcomes.

Indexed as

Biomarkers, TumorEpigenesis, GeneticGene Expression Regulation, NeoplasticNeoplasmsNeoplastic Cells, CirculatingAnimalsEpithelial-Mesenchymal TransitionHumansBiomarkers, TumorDisseminated tumor cellEpigenomeStemnessTumor biomarkerTumor dormancy

Identifiers

PMID41075028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.